SCHEMBL13848764

SCHEMBL13848764

CCc1c(C2=CN(c3cc(C(=O)Nc4cc(C(C)(C)C)cc(N)c4OC)ccc3C)NN2)cnn1C1CC1

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
BRAF P15056 20/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13848830 0.90 BRAF (0.45) BRAF
SCHEMBL13887611 0.87 BRAF (0.45) BRAF
SCHEMBL13848722 0.82 BRAF (0.47) BRAF
SCHEMBL13887682 0.80 BRAF (0.36) BRAF
SCHEMBL13848723 0.80 BRAF (0.45) BRAF
SCHEMBL13848778 0.80 BRAF (0.38) BRAF
SCHEMBL13848809 0.79 BRAF (0.36) BRAF
SCHEMBL13848970 0.79 BRAF (0.44) BRAF
SCHEMBL13848756 0.79 BRAF (0.47) BRAF
SCHEMBL13848788 0.79 BRAF (0.52) BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1725544-B1 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES BOEHRINGER INGELHEIM PHARMA (US) 2009-05-27 EP disclosed